(SLAB) Silicon Laboratories - NASDAQ
Sector: Technology | Industry: Semiconductors | Exchange: NASDAQ (USA) | Market Cap: 7.240m USD | Total Return: 55.8% in 12m
Avg Turnover: 85.3M
Qual. Beats: 1
Rev. Trend: -19.6%
Qual. Beats: 0
Warnings
High Debt/EBITDA (54.7) with thin interest coverage (-45.9)
Interest Coverage Ratio -45.9 is critical
Tailwinds
Supp Ema20
Silicon Laboratories Inc. (SLAB) is a fabless semiconductor company specializing in mixed-signal, analog-intensive integrated circuits. The firm focuses primarily on the Internet of Things (IoT) market, providing wireless microcontrollers and connectivity solutions for industrial, commercial, and consumer applications. Its portfolio supports diverse end-markets ranging from smart home automation and medical instrumentation to renewable energy infrastructure and industrial wearables.
Operating under a fabless business model, Silicon Labs outsources the physical fabrication of its silicon wafers to third-party foundries, allowing the company to focus capital on research, design, and intellectual property development. The IoT sector is characterized by high fragmentation, requiring semiconductor providers to support multiple wireless protocols such as Zigbee, Thread, Bluetooth, and Z-Wave to ensure device interoperability. The company reaches global markets through a combination of a direct sales force and a broad network of independent distributors.
Investors may find it useful to examine the companys long-term margin trends on ValueRay. Silicon Laboratories is headquartered in Austin, Texas, and has been a public entity since its founding in 1996.
- Inventory normalization cycles within the industrial and commercial IoT end markets
- Design win momentum for Matter and Zigbee wireless connectivity standards
- Revenue concentration in Chinese manufacturing and consumer electronics sectors
- Fabless operating margins sensitive to foundry pricing and wafer supply costs
- Adoption rates of smart metering and renewable energy infrastructure projects
| Net Income: -50.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -6.05 > 1.0 |
| NWC/Revenue: 66.28% < 20% (prev 76.09%; Δ -9.81% < -1%) |
| CFO/TA 0.04 > 3% & CFO 52.5m > Net Income -50.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.0m) vs 12m ago 1.53% < -2% |
| Gross Margin: 58.52% > 18% (prev 54.12%; Δ 4.39% > 0.5%) |
| Asset Turnover: 65.75% > 50% (prev 53.33%; Δ 12.42% > 0%) |
| Interest Coverage Ratio: -45.86 > 6 (EBIT TTM -42.3m / Interest Expense TTM 923k) |
| A: 0.43 (Total Current Assets 676.3m - Total Current Liabilities 132.5m) / Total Assets 1.27b |
| B: 0.73 (Retained Earnings 920.9m / Total Assets 1.27b) |
| C: -0.03 (EBIT TTM -42.3m / Avg Total Assets 1.25b) |
| D: 6.54 (Book Value of Equity 1.10b / Total Liabilities 167.9m) |
| Altman-Z'' = 11.83 = AAA |
| DSRI: 1.18 (Receivables 77.1m/52.1m, Revenue 820.5m/655.7m) |
| GMI: 0.92 (GM 54.12% / 58.52%) |
| AQI: 0.92 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 1.25 (Revenue 820.5m / 655.7m) |
| TATA: -0.08 (NI -50.3m - CFO 52.5m) / TA 1.27b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at USD 219.75 with a total of 735,041 shares traded.
Over the past week, the price has changed by +0.39%,
over one month by +1.45%,
over three months by +6.81% and
over the past year by +55.83%.
Silicon Laboratories has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold SLAB.
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 222.9 | 1.4% |
P/E Forward = 80.6452
P/S = 8.8228
P/B = 6.6154
P/EG = 3.1179
Revenue TTM = 820.5m USD
EBIT TTM = -42.3m USD
EBITDA TTM = -7.59m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 24.0m USD (Leases only: 24.0m)
Net Debt = -414.9m USD (calculated: Debt 24.0m - CCE 438.9m)
Enterprise Value = 6.82b USD (7.24b + Debt 24.0m - CCE 438.9m)
Interest Coverage Ratio = -45.86 (Ebit TTM -42.3m / Interest Expense TTM 923k)
EV/FCF = 387.6x (Enterprise Value 6.82b / FCF TTM 17.6m)
FCF Yield = 0.26% (FCF TTM 17.6m / Enterprise Value 6.82b)
FCF Margin = 2.15% (FCF TTM 17.6m / Revenue TTM 820.5m)
Net Margin = -6.13% (Net Income TTM -50.3m / Revenue TTM 820.5m)
Gross Margin = 58.52% ((Revenue TTM 820.5m - Cost of Revenue TTM 340.4m) / Revenue TTM)
Gross Margin QoQ = 56.65% (prev 63.44%)
Tobins Q-Ratio = 5.39 (Enterprise Value 6.82b / Total Assets 1.27b)
Interest Expense / Debt = 3.85% (Interest Expense 923k / Debt 24.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -33.4m (EBIT -42.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.11 (Total Current Assets 676.3m / Total Current Liabilities 132.5m)
Debt / Equity = 0.02 (Debt 24.0m / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = 54.66 (negative EBITDA) (Net Debt -414.9m / EBITDA -7.59m)
Debt / FCF = -23.56 (Net Debt -414.9m / FCF TTM 17.6m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.03% (Net Income -50.3m / Total Assets 1.27b)
RoE = -4.66% (Net Income TTM -50.3m / Total Stockholder Equity 1.08b)
RoCE = -3.73% (EBIT -42.3m / Capital Employed (Total Assets 1.27b - Current Liab 132.5m))
RoIC = -3.06% (negative operating profit) (NOPAT -33.4m / Invested Capital 1.09b)
WACC = 12.46% (E(7.24b)/V(7.26b) * Re(12.49%) + D(24.0m)/V(7.26b) * Rd(3.85%) * (1-Tc(0.21)))
Discount Rate = 12.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 1.54%
[DCF] Terminal Value 59.43% ; FCFF base≈47.2m ; Y1≈41.3m ; Y5≈33.4m
[DCF] Fair Price = 22.33 (EV 321.6m - Net Debt -414.9m = Equity 736.5m / Shares 33.0m; r=12.46% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.89 | # QB: 1
Revenue Correlation: -19.57 | Revenue CAGR: -4.53% | SUE: -0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.69 | Chg30d=-0.31% | Revisions=+25% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.82 | Chg30d=+0.05% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=2.75 | Chg30d=+0.30% | Revisions=+33% | GrowthEPS=+198.4% | GrowthRev=+17.7%
EPS next Year (2027-12-31): EPS=4.15 | Chg30d=+0.22% | Revisions=+25% | GrowthEPS=+51.1% | GrowthRev=+16.0%
[Analyst] Revisions Ratio: +33%